United pharmaceuticals (UPM) was created in 1989, with the main focus on manufacturing high-quality products for local markets and exports from Jordan.
In 2013, UPM joined MS Pharma group, which enabled the latter to unlock a wide range of synergies be-tween the affiliate companies of MS Pharma especially in terms of company strategic direction, portfolio focus and a platform for geographic expansion.
United Pharmaceuticals is a key regional player, fully equipped with a cutting edge facility and broad experience in the areas of pharmaceutical manufacturing, product development, market access, sales and marketing, warehousing, and distribution.
United Pharmaceuticals has established a very strong and solid presence in the Levant region but also in the matter of exports to the European countries after becoming the first company in the MENA region to obtain a European-GMP certificate.
United Pharmaceuticals operates in a facility covering 15,500 sq meters, employing the services of over 650 employees, and exports to more than 20 countries all around the world. Production is highly diversified, and the company currently manufactures more than 253 products in several dosage forms without compromising on reliability and quality.
Our generic business covers a broad range of therapeutic areas including: cardiovascular, central nervous system, respiratory, anti-infective, and anti-inflammatory and we are currently in the phase of consolidating our position in chronic diseases through extensive R&D activities and acquisition of licenses for new therapies.
Over the past 30 years, UPM has gained a very precise and accurate understanding of our regional market dynamics and customer needs. Through our marketing and sales activities, we leave no stone unturned to satisfy those needs in a professional manner.
At United Pharmaceuticals, we have strong research and development capabilities and expertise proven across different dosage forms, including complicated ones. The R&D center of UPM has efficient product development timelines. The center conducts the necessary research and development activities to develop and register new generic products, in addition to improving existing product specifications.
Today the R&D center of UPM is actively working to enrich the group portfolio with innovative products including generic plus, new combinations of medical products, and innovative drug delivery systems.
We are now registered and export to more than 20 locations around the world.
Our integrity has always made us the partner of choice for global investors who believe in the United Pharmaceutical experience, as we offer a strong and reliable partner to access and expand in the local market.